Abstracts Archive - Page 163 of 2607 - ACR Meeting Abstracts

Abstract Number: 0587 • ACR Convergence 2025
Regulatory Role of IL17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: IL-17A and IL-17F are the key inflammatory mediators in the IL-17 cytokine family (IL-17A to IL-17F). IL-17A is the widely recognized inflammatory cytokine in…
Abstract Number: 0637 • ACR Convergence 2025
DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
Sundus Dwidar¹, Mary Horton², Meghan Nelson³, Joanne Nititham², Richard Oppong³, Frank Donovan⁴, Jinoos Yazdany⁵, Maria Dall'Era⁶, Lisa Barcellos⁷, Heinner Guio⁸, Manuel Ugarte-Gil⁹, Lindsey Criswell² and Cristina Lanata¹⁰, ¹National Institutes of Health, Washington, ²NIH/NHGRI, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health, Bethesda, ⁵UCSF, San Francisco, CA, ⁶Division of Rheumatology, University of California, San Francisco, CA, ⁷UC Berkeley, Berkeley, ⁸Universidad de Huanuco, Lima, Peru, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ¹⁰NIH/NHGRI, Bethesda
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that disproportionately affects individuals of Amerindian ancestry and those who self-identify as Hispanic. The term “Hispanic”…
Abstract Number: 0673 • ACR Convergence 2025
Association Between Vasoactive-Vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence From a EUSTAR Study
Nicola Farina¹, Silvia Bellando-Randone², SEBASTIEN SANGES³, hilde Bjørkekjær⁴, lorenzo tofani⁵, Marie-Elise Truchetet⁶, Vanessa Smith⁷, Andra Balanescu⁸, Christina Bergmann⁹, Yannick Allanore¹⁰, Philipp Klemm¹¹, simona Truglia¹², Luca Idolazzi¹³, Christopher Denton¹⁴, Roberta Foti¹⁵, anna Wojteczek¹⁶, Emmanuel Chatelus¹⁷, Madelon Vonk¹⁸, Serena Guiducci¹⁹, David Launay²⁰, Eric Hachulla²¹, Jeska de Vries-Bouwstra²², Anna-Maria Hoffmann-Vold²³, Marco Matucci-Cerinic²⁴, Oliver Distler²⁵ and Cosimo Bruni²⁶, ¹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ²University of Florence, Florence, Florence, Italy, ³Medecine Interne CHRU Lille, Lille, France, ⁴Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, ⁵Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷Ghent University Hospital, Gent, Belgium, ⁸UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹⁰Université Paris Cité, Paris, France, ¹¹Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ¹²Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy, rome, Italy, ¹³Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, ¹⁴University College London, UK, London, United Kingdom, ¹⁵Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy, Catania, Italy, ¹⁶Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdańsk, University Clinical Centre, Gdańsk, Poland, Gdańsk, Poland, ¹⁷Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹⁸Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ²⁰Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ²¹University of Lille, LILLE, France, ²²Leiden University Medical Center, Leiden, Netherlands, ²³Oslo University Hospital, Oslo, Norway, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁶University of Zurich, Zurich, Switzerland
Background/Purpose: Vasoactive-vasodilating drugs (VVD) are the cornerstone of the treatment of pulmonary arterial hypertension (PAH), a form of precapillary pulmonary hypertension (pPH) that represents a…
Abstract Number: 0595 • ACR Convergence 2025
Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
Rangi Kandane-Rathnayake¹, Yi-Hsing Chen², Alberta Hoi³, Vera Golder⁴, Worawit Louthrenoo⁵, Jiacai Cho⁶, Aisha Lateef⁷, Laniyati Hamijoyo⁸, Shue Fen Luo⁹, Yeong-Jian Jan Wu¹⁰, Chiu Wai Shirley Chan¹¹, Leonid Zamora¹², Yasuhiro Katsumata¹³, Sargunan Sockalingam¹⁴, Zhanguo Li¹⁵, Haihong Yao¹⁵, BMDB Basnayake¹⁶, Yih Jia Poh¹⁷, Yanjie Hao¹⁸, Zhuoli Zhang¹⁹, Madelynn Chan²⁰, Jun Kikuchi²¹, Yuko Kaneko²², Tsutomu Takeuchi²³, Shereen Oon²⁴, Kristine Ng²⁵, Sang-Cheol Bae²⁶, Cherica Tee²⁷, Michael Tee²⁷, Nicola Tugnet²⁸, Sean O’Neill²⁹, Geraldine Hassett³⁰, Fiona Goldblatt³¹, Naoaki Ohkubo³², Yusuke Miyazaki³², Mark Sapsford³³, Yoshiya Tanaka³⁴, Sandra Navarra³⁵, Chak Sing Lau³⁶, Mandana Nikpour³⁷ and Eric Morand³⁸, ¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ²Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ³Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ⁷Woodlands Health, Singapore, Singapore, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ⁹Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁰Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan (Republic of China), ¹¹Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹²University of Santo Tomas Hospital, Manila, Philippines, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴University of Malaya Medical Center, Kuala Lumpur, Malaysia, ¹⁵Peking University People's Hospital, Beijing, China (People's Republic), ¹⁶National Hospital Kandy, Kandy, Sri Lanka, ¹⁷Singapore General Hospital, Singapore, Singapore, ¹⁸St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹⁹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²⁰Tan Tock Seng Hospital, Singapore, Singapore, ²¹Keio University, Tokyo, Japan, ²²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²³Saitama Medical University and Keio University, Tokyo, Japan, ²⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ²⁵Health New Zealand Waitemata, Te Whatu Ora, Auckland, New Zealand, ²⁶Hanyang University Medical Center, Seoul, South Korea, ²⁷University of the Philippines, Manila, Philippines, ²⁸Health New Zealand Auckland, Te Whatu Ora (Auckland District Health Board), Auckland, New Zealand, ²⁹The University of Sydney, Sydney, Australia, ³⁰Liverpool Hospital, NSW, Liverpool, Australia, ³¹Flinders Medical Centre, Bedford park, Australia, ³²University of Occupational and Environmental Health, Kitakyushu, Japan, ³³Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital),, Auckland, New Zealand, ³⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³⁵University of Santo Tomas, Manila, Philippines, ³⁶The University of Hong Kong, Hong Kong, Hong Kong, ³⁷University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, ³⁸Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) states in SLE, such as the Lupus Low Disease Activity State (LLDAS) and remission (REM) as defined by the Definitions of Remission…
Abstract Number: 0698 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Systemic sclerosis (SSc) or scleroderma is a rare systemic autoimmune disease with multiple organ involvement. Renal involvement in SSc remains a significant concern, with…
Abstract Number: 0600 • ACR Convergence 2025
Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
Ahlam Almarzooqi¹, Sarah Al Qassimi², Nelly Ziade³, Mohammed Omair⁴, Samar Al emadi⁵, FARIDA ALBALUSHI⁶, Waleed Hafiz⁷, Hiba Khogali⁸, Saadeya Naji⁹, Suzan Attar¹⁰, Khalid Alnaqbi¹¹ and Rajaie Namas¹², ¹Emirates Health Services, Sharjah, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ⁴King Saud university, Riyadh, Saudi Arabia, ⁵Hamad medical corporation, Doha, Qatar, ⁶Royal hospital, Dubia, United Arab Emirates, ⁷Umm Al-Qura university, Makkah, Makkah, Saudi Arabia, ⁸Madinat Zayed Hospital , Al Dhafra hospitals, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁹Salmaniya medical complex, BAHRAIN, Al Asimah, Bahrain, ¹⁰King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ¹¹Sheikh Tahnoon Medical city, Al Ain, United Arab Emirates, ¹²Cleveland Clinic Abu Dhabi, Detroit, MI
Background/Purpose: Difficult-to-treat systemic lupus erythematosus (D2T-SLE) presents a major challenge due to disease heterogeneity and a lack of unified classification. While the D2T concept has…
Abstract Number: 0609 • ACR Convergence 2025
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Eleni Papachristodoulou¹ and Vasileios Kyttaris², ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…
Abstract Number: 0699 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is one of the life threatening complications of systemic sclerosis (SSc). Up to 20-50% require long term dialysis and subsequently…
Abstract Number: 0645 • ACR Convergence 2025
Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Eric Morand¹, Lucy Carter², Maria Dall'Era³, Michelle Petri⁴, Ed Vital⁵, Teri Jimenez⁶, Janine Gaiha-Rohrbach⁷, Bernard Lauwerys⁸, Annette Nelde⁹, Christian Stach¹⁰ and Ronald van Vollenhoven¹¹, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Division of Rheumatology, University of California, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶UCB, Raleigh, NC, ⁷Biogen, Cambridge, MA, ⁸Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ⁹Biogen, Baar, Switzerland, ¹⁰UCB, Monheim am Rhein, Germany, ¹¹Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects on SLE immunopathology;1,2 it consists of a polyethylene glycol (PEG)-conjugated antigen-binding fragment…
Abstract Number: 0708 • ACR Convergence 2025
Association Of Choroidal Sub-foveal Thickness With Skin Manifestations And Serum Monocyte HDL Ratio In Patients With Systemic Sclerosis-A Case Control Study
Tejaswini Ramineni¹, Vijaya prasanna Parimi², Radhika M³ and Narsimulu Gumdal³, ¹Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India, ²ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ³ESIC MEDICAL COLLEGE AND HOSPITAL, Hyderabad, Telangana, India
Background/Purpose: The vascular hypothesis in systemic sclerosis (SSc) posits that vasculopathy is the initial inciting event that triggers inflammation and subsequent fibrosis in the progression…
Abstract Number: 0696 • ACR Convergence 2025
Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis
Jeska de Vries-Bouwstra¹, Jingjing He², Xu Wang², Saad Ahmed², Jeroen J. Bax² and Nina Ajmone Marsan², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Myocardial involvement in systemic sclerosis (SSc) represents a severe complication with a poor prognosis; however, compromised cardiac function also heightens the risk of life-threatening…
Abstract Number: 0611 • ACR Convergence 2025
Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Fadi Kharouf¹, Pankti Mehta², Qixuan Li², Dafna D. Gladman³, Laura Whitall Garcia⁴ and Zahi Touma⁵, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus…
Abstract Number: 0613 • ACR Convergence 2025
A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort
Fadi Kharouf¹, Pankti Mehta², Qixuan Li³, Dafna D. Gladman⁴, Zahi Touma⁵ and Laura Whitall Garcia⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada
Background/Purpose: Baseline kidney biopsy is the gold standard for diagnosing incident lupus nephritis (LN). However, in certain cases, obtaining a biopsy may not be feasible…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 0703 • ACR Convergence 2025
Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023
Nicolas Barnechea Alvarado¹, Khadija Mohib¹, Rameez Qasim² and Muhammad Ali³, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³Dow International Medical College, Karachi, Sindh, Pakistan
Background/Purpose: Systemic sclerosis is one of the most fatal rheumatologic diseases, with significantly higher mortality rates compared to the general population, likely due to its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].